A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS).

Trial Profile

A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2012

At a glance

  • Drugs Desirudin (Primary) ; Argatroban
  • Indications Embolism and thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome
  • Focus Therapeutic Use
  • Acronyms PREVENT-HIT
  • Sponsors Canyon Pharmaceuticals
  • Most Recent Events

    • 15 Apr 2010 Results were presented at the Hemophilia & Thrombosis Research Society 2010 Scientific Symposium held in Chicago, Illinois, USA, as reported by a Canyon Pharmaceuticals media release. Actual number of patients and trial acronym added.
    • 01 Apr 2010 Rationale and design of this study has been published in full in the journal Clinical Therapeutics: 32; 4.
    • 20 Jan 2010 Status changed from recruiting to discontinued (due to low enrollment) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top